Barry J. Maron

Heart Failure / Cardiomyopathy

Lahey Hospital and Medical Center

About

Barry J. Maron works in Heart Failure / Cardiomyopathy affiliated with Lahey Hospital and Medical Center.

Barry J. Maron, MD is a cardiologist at the Hypertrophic Cardiomyopathy Center at Lahey Hospital & Medical Center in Burlington, Massachusetts. He is an Adjunct Professor of Medicine at UMass Chan Medical School and Tufts University School of Medicine. He previously served as Director of the Hypertrophic Cardiomyopathy Center at the Minneapolis Heart Institute Foundation and as Senior Investigator at the National Heart, Lung, and Blood Institute.

Research focus

Hypertrophic CardiomyopathySudden Death Prevention in HCMImplantable Cardioverter-DefibrillatorsAthlete's HeartRisk Stratification in Cardiomyopathy

Impact

1,163 pubs · 116,796 cites · h-index 171

Training

MD
Tulane University School of Medicine
1968
BA
Occidental College
1963

Affiliations

Work Experience

Cardiologist, Hypertrophic Cardiomyopathy Center

Lahey Hospital and Medical Center · 2022 - Present

Adjunct Professor of Medicine

UMass Chan Medical School · 2022 - Present

Director of Clinical Research, Hypertrophic Cardiomyopathy Center

Tufts Medical Center · 2016 - 2022

Director, Hypertrophic Cardiomyopathy Center

Minneapolis Heart Institute Foundation · 1993 - 2016

Senior Investigator, Cardiology Branch

National Heart, Lung, and Blood Institute · 1972 - 1993

Publications

Original Research

NOV 2MaronCirculation

Eugene Braunwald Legacy Series: The Father of Hypertrophic Cardiomyopathy

2d ago

MaronCirculation

Eugene Braunwald Legacy Series: The Father of Hypertrophic Cardiomyopathy

Original Research12 mentionsJACC Highlight

JUN 2016MaronJournal of the American College of Cardiology

The Father of Septal Myectomy for Obstructive HCM, Who Also Had HCM

Jun 2016Open Access

EditorialJACC Highlight

MaronJournal of the American College of Cardiology

The Father of Septal Myectomy for Obstructive HCM, Who Also Had HCM

Original Research

AUG 1MaronJournal of the American College of Cardiology

Surgical Myectomy for Symptomatic Obstructive Hypertrophic Cardiomyopathy

13w ago

Editorial

MaronJournal of the American College of Cardiology

Surgical Myectomy for Symptomatic Obstructive Hypertrophic Cardiomyopathy

Original Research

AUG 1MaronJournal of the American College of Cardiology

Hypertrophic Cardiomyopathy

13w ago

MaronJournal of the American College of Cardiology

Hypertrophic Cardiomyopathy

cross-sectional · n=1,959JACC Highlight

JUN 2008MagalskiJournal of the American College of Cardiology

Black race linked to ~103% higher rate of abnormal ECG patterns in elite football players.

Black race is an independent determinant of abnormal ECG patterns in highly-trained male American football players, highlighting the need to consider race during pre-participation cardiovascular screening.

Jun 2008Open Access

JACC Highlight

Level 4: Cross-Sectional

MagalskiJournal of the American College of Cardiology

Black race linked to ~103% higher rate of abnormal ECG patterns in elite football players.

Implication

Original Research12 mentionsJACC Highlight

SEP 2005RobertsJournal of the American College of Cardiology

Evidence for Decreasing Occurrence of Sudden Cardiac Death Associated With the Marathon

Sep 2005Open Access

JACC Highlight

RobertsJournal of the American College of Cardiology

Evidence for Decreasing Occurrence of Sudden Cardiac Death Associated With the Marathon

Original Research9 mentionsJACC Highlight

NOV 2015MaronJournal of the American College of Cardiology

Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 3: Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis

Nov 2015Open Access

JACC Highlight

MaronJournal of the American College of Cardiology

Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 3: Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis

Retrospective Study14 mentionsJACC Highlight

JAN 2002MaronJournal of the American College of Cardiology

Non-anticoagulation linked to ~72% greater stroke and vascular risk versus warfarin in HCM with AF.

Cohort study reveals stroke frequency and thromboembolic outcomes in hypertrophic cardiomyopathy, highlighting atrial fibrillation as a primary driver.

Jan 2002Open Access

JACC Highlight

Level 4: Retrospective

MaronJournal of the American College of Cardiology

Non-anticoagulation linked to ~72% greater stroke and vascular risk versus warfarin in HCM with AF.

Implication

Cohort study reveals stroke frequency and thromboembolic outcomes in hypertrophic cardiomyopathy, highlighting atrial fibrillation as a primary driver.

Kevin M. Harris

Cardiologist, Minneapolis Heart Institute at Abbott Northwestern · Minneapolis Heart Institute Foundation

10d

The widespread screening process failed to detect important cardiovascular abnormalities in 19 of the deaths. In the remaining 15 cases, suspicion of cardiovascular conditions was raised, but the athletes were allowed to continue to compete in competitive sports.

Under-Recognition of Aortic and Aortic Valve Disease and the Risk for Sudden Death in Competitive Athletes

Journal of the American College of CardiologyHarris et al.Feb 2015

Original Research10 mentionsJACC Highlight

NOV 2015BravermanJournal of the American College of Cardiology

Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 7: Aortic Diseases, Including Marfan Syndrome

Nov 2015Open Access

JACC Highlight

BravermanJournal of the American College of Cardiology

Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 7: Aortic Diseases, Including Marfan Syndrome

Barry Maron

Director, Hypertrophic Cardiomyopathy Center, Minneapolis Heart Institute Foundation

The only thing excluded is national screening.

Assessment of the 12-Lead ECG as a Screening Test for Detection of Cardiovascular Disease in Healthy General Populations of Young People (12–25 Years of Age)

CirculationMaron et al.Sep 2014

cohort · n=8707 mentionsJACC Highlight

AUG 2008OlivottoJournal of the American College of Cardiology

Left ventricular mass index by cardiovascular magnetic resonance was significantly higher in HCM patients than controls (P<0.0001), yet remained within the normal range in 21% of patients.

Increased left ventricular mass by CMR is not a requirement for establishing the clinical diagnosis of HCM, as it is normal in about 20% of patients, though it is a sensitive predictor of clinical outcomes.

Aug 2008Open Access

JACC Highlight

Level 3: Cohort Study

OlivottoJournal of the American College of Cardiology

Left ventricular mass index by cardiovascular magnetic resonance was significantly higher in HCM patients than controls (P<0.0001), yet remained within the normal range in 21% of patients.

Implication

Original Research7 mentionsJACC Highlight

APR 2005MaronJournal of the American College of Cardiology

Introduction: Eligibility recommendations for competitive athletes with cardiovascular abnormalities—general considerations

Apr 2005Open Access

JACC Highlight

MaronJournal of the American College of Cardiology

Introduction: Eligibility recommendations for competitive athletes with cardiovascular abnormalities—general considerations

case-control · n=1169 mentionsJACC Highlight

SEP 1986MaronJournal of the American College of Cardiology

HCM linked to ~9-fold higher prevalence of abnormal intramural coronary arteries at necropsy vs controls.

Abnormal intramural coronary arteries with thickened walls and narrowed lumens are highly prevalent in patients with hypertrophic cardiomyopathy and may contribute to myocardial ischemia and fibrosis.

Sep 1986Open Access

JACC Highlight

Level 4: Case-Control

MaronJournal of the American College of Cardiology

HCM linked to ~9-fold higher prevalence of abnormal intramural coronary arteries at necropsy vs controls.

Implication

cross-sectional · n=1777 mentionsJACC Highlight

APR 2008AdabağJournal of the American College of Cardiology

Delayed enhancement on CMR is linked to ~630% greater NSVT risk in HCM.

Myocardial fibrosis detected by delayed enhancement on CMR identifies hypertrophic cardiomyopathy patients with an increased susceptibility to ventricular tachyarrhythmias.

Apr 2008Open Access

JACC Highlight

Level 4: Cross-Sectional

AdabağJournal of the American College of Cardiology

Delayed enhancement on CMR is linked to ~630% greater NSVT risk in HCM.

Implication

Myocardial fibrosis detected by delayed enhancement on CMR identifies hypertrophic cardiomyopathy patients with an increased susceptibility to ventricular tachyarrhythmias.

cohort · n=3,3875 mentionsTrending on XFeatured in Podcast

AUG 25RowinCirculation

Implantable cardioverter-defibrillators delivered appropriate therapy to 16% of patients with hypertrophic cardiomyopathy over a mean follow-up of 7 years, with low HCM-related mortality.

In a large international cohort of HCM patients, ICDs effectively terminated life-threatening arrhythmias in 16% of patients, resulting in very low rates of sudden death and high long-term survival.

10w ago

Trending on XFeatured in Podcast

Level 3: Cohort Study

RowinCirculation

Implantable cardioverter-defibrillators delivered appropriate therapy to 16% of patients with hypertrophic cardiomyopathy over a mean follow-up of 7 years, with low HCM-related mortality.

Implication

In a large international cohort of HCM patients, ICDs effectively terminated life-threatening arrhythmias in 16% of patients, resulting in very low rates of sudden death and high long-term survival.

This Week in Cardiology: Oct 09 2026 This Week in Cardiology

Jonathan H. Kim

Director of sports cardiology, Emory University · Emory University School of Medicine

2mo

In the past, there was no shared decision-making about sports eligibility for athletes with heart disease. These athletes were automatically prohibited from participating in sports if almost any cardiac issue was present.

Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 3: Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis

CirculationMaron et al.Nov 2015

Barry J. Maron

Director, Hypertrophic Cardiomyopathy Center, Minneapolis Heart Institute Foundation · Minneapolis Heart Institute Foundation

2mo

Although the frequency of these deaths in young athletes appears to be relatively low, it is more common than previously thought and does represent a substantive public health problem.

Recommendations and Considerations Related to Preparticipation Screening for Cardiovascular Abnormalities in Competitive Athletes: 2007 Update

CirculationMaron et al.Mar 2007

Katherine A. Martinez

Research intern, Mayo Clinic Sudden Death Genomic Laboratory · Mayo Clinic / Loyola University Maryland

2mo

This limited these athletes to bowling, cricket, curling, golf, riflery and yoga. At this time, these guidelines were not based on observational data, but out of an abundance of caution for disease, with a potential exercise-induced sudden death risk.

26th Bethesda Conferance: Recommendations for determining eligibility for competetion in athletes with cardiovascular abnormalities

Journal of the American College of CardiologyMaron et al.Oct 1994

Iacopo Olivotto

Cardiomyopathy specialist, Careggi University Hospital, Florence · Careggi University Hospital

2mo

oHCM is a neglected disease that affects millions of people worldwide and for which there is no licensed drug. We see the disease progressing and we have nothing to counter it.

The 50-Year History, Controversy, and Clinical Implications of Left Ventricular Outflow Tract Obstruction in Hypertrophic Cardiomyopathy

Journal of the American College of CardiologyMaron et al.Jul 2009

All publications →